Literature DB >> 32306944

Socioeconomic variations in chronic obstructive pulmonary disease prevalence, diagnosis, and treatment in rural Southwest China.

Le Cai1, Xu-Ming Wang2,3, Lu-Ming Fan2, Jing-Rong Shen2, Ying-Nan Liu2, Allison Rabkin Golden2.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major and growing cause of morbidity and mortality throughout the world. However, there remains a limited understanding of the association between individual socioeconomic status (SES) and COPD diagnosis and treatment worldwide, including in China. This study investigates socioeconomic variations in prevalence, diagnosis, and treatment of COPD in rural China.
METHODS: The present study employed a cross-sectional survey design. The study population was composed of Han majority as well as Na Xi and Bai ethnic minority individuals 35 years of age and older living in Yunnan Province from 2017 to 2019. In total, 7534 individuals consented to participate in the study and complete a structured interview as well as a post-bronchodilator spirometry test. Multivariate logistic regression was used to analyze the association between individual socioeconomic status variables and the prevalence, diagnosis, and treatment of COPD.
RESULTS: The age-standardized prevalence of COPD in the present study was 14.3%. Prevalence differed by gender: prevalence for men was 17.1%, versus 11.4% for women (P = 0.0001). Overall, levels of diagnosis and treatment of COPD for participants with COPD were 24.2 and 23.1%, respectively. Multivariate logistic regression indicated that higher educational levels and good access to medical services was associated with an overall lower risk of COPD (P = 0.032 vs. P = 0.018) as well as a higher probability of COPD diagnosis among those with COPD (P = 0.0001 vs. P = 0.002). Participants with COPD with higher educational levels (P = 0.0001) and higher annual household incomes (P = 0.0001) as well as good access to medical services (P = 0.016) were more likely to receive COPD medications and treatment than their counterparts. While Na Xi and Bai participants had a higher probability of having COPD (P = 0.0001), they had a lower probability of having received a diagnosis or treatment for COPD than Han participants (P = 0.0001 vs. P = 0.0012).
CONCLUSIONS: Future interventions to further control COPD and improve diagnosis and treatment should focus on ethnic minority communities, and those with low education levels, low annual household incomes, and poor access to medical services.

Entities:  

Keywords:  China; Chronic obstructive pulmonary disease; Diagnosis; Socioeconomic status; Treatment

Year:  2020        PMID: 32306944     DOI: 10.1186/s12889-020-08687-5

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  4 in total

1.  Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study.

Authors:  Kjell Larsson; Karin Lisspers; Björn Ställberg; Gunnar Johansson; Florian S Gutzwiller; Karen Mezzi; Bine Kjoeller Bjerregaard; Leif Jorgensen; Hyewon Koo; Christer Janson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-21

2.  Socioeconomic differentials in trends in the prevalence of hypertension and pre-hypertension and hypertension awareness, treatment, and control in rural Southwestern China.

Authors:  Lu-Ming Fan; Fang Wang; Min Zhao; Wen-Long Cui; Le Cai
Journal:  BMC Cardiovasc Disord       Date:  2021-05-26       Impact factor: 2.298

3.  Analysis of diagnostic delay and its influencing factors in patients with chronic obstructive pulmonary disease: a cross-sectional study.

Authors:  Zhongshang Dai; Yiming Ma; Zijie Zhan; Ping Chen; Yan Chen
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

4.  The trend in primary health care preference in China: a cohort study of 12,508 residents from 2012 to 2018.

Authors:  Guangsheng Wan; Xiaolin Wei; Hui Yin; Zhiwang Qian; Tingting Wang; Lina Wang
Journal:  BMC Health Serv Res       Date:  2021-08-03       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.